Search Browse Earnings

Cocrystal Pharma, Inc.

Nasdaq:COCP

Pharmaceutical Preparations·BOTHELL, WA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Cocrystal Pharma, Inc. — SlamSEC

Revenue

$2.0M

-69.3% YoY

FY 2021

Adj. EBITDA

-$18.4M

-912.1% margin

FY 2024

Net Income

-$18.0M

-892.9% margin

FY 2024

EPS (Diluted)

-$1.87

FY 2024

Stock Price

$1.08

+6.9%

2026-03-16

52W Range

$0.86 – $2.67

P/E Ratio

-0.6x

Market Cap

$14.9M

Cash

$26.4M

FY 2024

Total Debt

$65.5M

FY 2015

Net Debt

$39.2M

FY 2015

Enterprise Value

$54.1M

Debt / EBITDA

-2.1x

FY 2021

EV / EBITDA

-2.9x

Employees

—

" Several subclassifications of cocrystals exist.

CEO

Lee Sam